Piper Sandler Raises Insulet (NASDAQ:PODD) Price Target to $310.00
Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...
Insulet’s (PODD) Outperform Rating Reiterated at Raymond James
Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...
Hosted on MSN2d
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...
Hosted on MSN2d
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise
Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...
Insulet: Aiding Patients And Investors
Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...
Insulet beats quarterly profit estimates on insulin pump demand
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Prothena (PRTA) and Travere Therapeutics (TVTX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...
Zacks.com on MSN2d
Insulet (PODD) Q4 Earnings and Revenues Top Estimates
Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo Finance9d
Insulet Corporation (PODD)
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...